Analyzing Cutera (NASDAQ:CUTR) and SpectraScience (NASDAQ:SCIE)

Share on StockTwits

Cutera (NASDAQ:CUTR) and SpectraScience (OTCMKTS:SCIE) are both computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Valuation and Earnings

This table compares Cutera and SpectraScience’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cutera $162.72 million 2.10 -$30.77 million ($2.23) -10.94
SpectraScience N/A N/A -$4.46 million N/A N/A

SpectraScience has lower revenue, but higher earnings than Cutera.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cutera and SpectraScience, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cutera 0 2 2 0 2.50
SpectraScience 0 0 0 0 N/A

Cutera currently has a consensus price target of $34.67, suggesting a potential upside of 42.08%.

Institutional & Insider Ownership

92.6% of Cutera shares are held by institutional investors. Comparatively, 0.0% of SpectraScience shares are held by institutional investors. 2.3% of Cutera shares are held by company insiders. Comparatively, 0.5% of SpectraScience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Cutera and SpectraScience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cutera -22.45% -65.62% -34.41%
SpectraScience N/A N/A N/A

Risk & Volatility

Cutera has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, SpectraScience has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500.

Summary

SpectraScience beats Cutera on 5 of the 9 factors compared between the two stocks.

Cutera Company Profile

Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. It also provides excel V, a vascular and benign pigmented lesion treatment platform; xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; Juliet, a laser system for vaginal health; and Secret RF, a fractional radio frequency microneedling device for skin revitalization. In addition, the company offers GenesisPlus, CoolGlide, myQ, enlighten SR, and truSculpt iD products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills and marketing brochures through the Internet. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, physicians performing aesthetic treatments in non-medical offices, and other qualified practitioners, as well as for physicians offering aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California.

SpectraScience Company Profile

SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. It offers WavSTAT3 optical biopsy system to determine whether a colon tissue is normal, pre-cancerous, or cancerous without physically removing tissue from the body; and WavSTAT4 optical biopsy system, a colon diagnostic product that operates by using UV laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer. The company also sells mobile consoles and disposable forceps. In addition, it engages in developing an esophageal diagnosis application for the detection of pre-cancerous and cancerous tissues in various tissues of the body. The company was formerly known as GV Medical, Inc. and changed its name to SpectraScience, Inc. in October 1992. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California.

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

IceChain Reaches 1-Day Volume of $4.00
IceChain Reaches 1-Day Volume of $4.00
Elitium  Price Hits $1.23
Elitium Price Hits $1.23
Zacks: Analysts Anticipate BlackBerry Ltd  to Post -$0.01 Earnings Per Share
Zacks: Analysts Anticipate BlackBerry Ltd to Post -$0.01 Earnings Per Share
CyberFM Market Capitalization Achieves $805,684.00
CyberFM Market Capitalization Achieves $805,684.00
Columbia Sportswear  Expected to Post Earnings of $1.54 Per Share
Columbia Sportswear Expected to Post Earnings of $1.54 Per Share
Air Products & Chemicals, Inc.  Given Average Rating of “Buy” by Brokerages
Air Products & Chemicals, Inc. Given Average Rating of “Buy” by Brokerages


© 2006-2019 Ticker Report